Pyros and Anovo Partner to Elevate Care for Infantile Spasms
April 1, 2024
Pyros Pharmaceuticals works to elevate the standard of care for children with rare disease by pioneering treatment options like VIGPODER™ (vigabatrin), a breakthrough treatment for infantile spasms.
What is West syndrome?
Infantile spasms, sometimes called West syndrome, are a type of seizure that affects babies. Although symptoms usually begin to show when infants are between 4 and 7 months old, spasms can start any time in the first few years of life. Infantile spasms look like a sudden stiffening of the muscles and occur in short bursts of about one to two minutes at a time – and affected babies can experience up to 100 seizures per day. Children with infantile spasms require treatment quickly after the onset of spasms or there is a risk of negative effects on the development of the child’s brain.
Pyros Pharmaceuticals Partners with Anovo
Our team at Anovo would like to extend heartfelt congratulations to Pyros Pharmaceuticals for the launch of VIGPODER™ (vigabatrin). We are honored to be chosen as the exclusive distributor and specialty pharmacy for this innovative medication. We believe in the potential of VIGPODER™ and its capacity to make a meaningful difference in the lives of those affected by infantile spasms.
Related Posts
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
